United Therapeutics (UTHR) EBIT Growth (1y) (2010 - 2026)
Powered by 
Analysis
United Therapeutics (UTHR) EBIT Growth (1y) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 642.97 Bn | 622.21 Bn | 17.26 Bn | 7.43% |
| 2 | AbbVie | 441.24 Bn | 434.67 Bn | 12.70 Bn | 31.43% |
| 3 | Merck | 364.65 Bn | 357.51 Bn | 12.21 Bn | -111.70% |
| 4 | Novartis Ag | 266.30 Bn | 258.61 Bn | 11.24 Bn | -2.34% |
| 5 | Pfizer | 158.95 Bn | 147.25 Bn | 10.94 Bn | -15.58% |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | -27.06% |
| 7 | Revolution Medicines | 44.29 Bn | 44.29 Bn | - | - |
| 8 | Incyte | 25.27 Bn | 20.73 Bn | 1.57 Bn | 31.60% |
| 9 | United Therapeutics | 21.44 Bn | 18.78 Bn | 683.80 Mn | -9.25% |
| 10 | Neurocrine Biosciences | 15.52 Bn | 15.13 Bn | 935.80 Mn | 4.05% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -9.25% |
| Mar 31, 2026 | -14.89% |
| Dec 31, 2025 | -0.28% |
| Sep 30, 2025 | 13.23% |
| Jun 30, 2025 | 13.94% |
| Mar 31, 2025 | 7.44% |
| Dec 31, 2024 | 37.52% |
| Sep 30, 2024 | 4.92% |
| Jun 30, 2024 | 2.07% |
| Mar 31, 2024 | 25.28% |
| Dec 31, 2023 | 48.12% |
| Sep 30, 2023 | 4.04% |
| Jun 30, 2023 | 55.30% |
| Mar 31, 2023 | -1.25% |
| Dec 31, 2022 | 3.42% |
| Sep 30, 2022 | 37.43% |
| Jun 30, 2022 | -9.18% |
| Mar 31, 2022 | 544.44% |
| Dec 31, 2021 | 160.03% |
| Sep 30, 2021 | 3.44% |